Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Humira Designated as Orphan Drug for Hidradenitis Suppurativa: AbbVie
October 5, 2017
- Sato, Eisai to Copromote Oral Onychomycosis Drug
October 4, 2017
- Takeda’s Oral Relugolix Scores Non-Inferiority vs Leuprorelin in Uterine Fibroids: Japan PIII
October 4, 2017
- Takeda-Backed Chromatography Startup Launched at Shonan Research Center
October 4, 2017
- Trazenta-Jardiance Combo Filed in Japan: Lilly/Boehringer
October 4, 2017
- EA Pharma, Mochida in Tie-Up Deal for 2nd Constipation Med
October 4, 2017
- Torii Named CEO of Fujifilm-Kyowa Kirin JV after Humira Biosimilar Filing
October 4, 2017
- JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
October 4, 2017
- Celgene Looks to Expand Footprint in Japan Unmet Need Arena
October 4, 2017
- Japan Debut of MSD’s Zetia/Lipitor Combo Delayed as Cyberattack Woes Continue
October 4, 2017
- Shoichiro Ogawa Tapped as Alcon Pharma Japan Chief
October 3, 2017
- Olaparib Gets Orphan Status for BRCA-Mutated Breast Cancer
October 3, 2017
- Astellas to Launch 3-Way Copromotion Scheme for Kiklin
October 3, 2017
- Yoshindo Licenses Nesp Biosimilar from South Korea’s CJ Healthcare
October 3, 2017
- AZ Contesting Employee Lawsuits; First Oral Arguments Held at Tokyo District Court
October 3, 2017
- JCR Files Fabrazyme Biosimilar for Japan Approval
October 3, 2017
- SI-613 Enters PIIb Study for Enthesopathy: Ono, Seikagaku
October 3, 2017
- Takeda Links with Swedish, Canadian Organizations on IBD Research
October 2, 2017
- Opdivo-Yervoy Combo Filed in Japan for Melanoma
October 2, 2017
- Alexandre de Muralt to Lead Merck Serono Japan
September 29, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…